Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023.
Second Quarter Financial Highlights
- Total revenue was $31.0 million versus prior year second quarter total revenue of $23.5 million, an increase of 32%. Second quarter revenue also increased 9% sequentially driven by increased Accelerator Lab and consumables revenue. Second quarter revenue includes a one-time benefit of approximately $1.5 million related to product and license agreements.
- GAAP gross margin was 61.7% compared to prior year second quarter GAAP gross margin of 37.1%. Non-GAAP gross margin was 56.4% compared to prior year second quarter non-GAAP gross margin of 29.1%.
- Net loss was $6.1 million compared to prior year second quarter net loss of $24.9 million.
- Net cash flow in the quarter was approximately break-even. Cash and cash equivalents were $329.5 million as of June 30, 2023, as compared to $329.4 million as of March 31, 2023.
“Since launching our corporate transformation, we’re pleased with the accelerating progress as evidenced by both financial and business results,” said Masoud Toloue, President and Chief Executive Officer of Quanterix. “In under a year, our talented team has implemented fundamental change to business operations, with cash flow break-even being a key milestone, that said, we intend to continue to invest in scaling and supporting the important work performed on our Simoa® platform, that we believe will change the way we understand, test, and treat neurological diseases.”
Operational and Business Highlights
Accelerating our leadership position in blood-based biomarkers:
- In July, the Company launched LucentAD, a blood-based biomarker test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease. This launch includes a new portal for patient and providers.
- Positive readout on Quanterix’s Bio-Hermes clinical study with the Global Alzheimer’s Platform Foundation confirmed high correlation between the LucentAD blood test and amyloid PET scans in early Alzheimer’s patients, a cohort most eligible for therapy. Results will be used to support Quanterix’s FDA filing.
- Quanterix’s Accelerator Lab will now provide Simoa assay testing for tau phosphorylation at residues 217 and 212 (p217+ tau), through a new research use only agreement with Janssen for its proprietary p217+ tau assays. Published studies have shown that the presence of phosphorylated tau in plasma is predictive of central amyloid and tau status and has the potential for diagnosing and staging Alzheimer’s disease.
- Robust reference dataset of serum NfL levels measured using Simoa technology across a wide spectrum of ages, from neonatal to 20-year-old adolescents, was published last week in Lancet Neurology, establishing a new standard with important implications on neuro-testing.
Full Year Business Outlook
With accelerating corporate transformation efforts, management has increased full-year revenue expectations to be in the range of $110 to $116 million, GAAP gross margin percentage to be in the low 50s, and non-GAAP gross margin percentage to be in the high 40s. The Company also anticipates a lower 2023 cash burn, in the range of $30 to $35 million.
For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Conference Call
In conjunction with this announcement, the Company will host a conference call on August 8, 2023 at 8:30 a.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode.
Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.
Financial Highlights
Quanterix Corporation | ||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||
(Unaudited and in thousands, except per share data) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue | $ | 19,692 | $ | 14,785 | $ | 38,979 | $ | 35,441 | ||||||||
| Service revenue | 10,552 | 8,548 | 19,131 | 17,358 | ||||||||||||
| Collaboration and license revenue | 629 | 92 | 997 | 178 | ||||||||||||
| Grant revenue | 156 | 75 | 378 | 75 | ||||||||||||
| Total revenues | 31,029 | 23,500 | 59,485 | 53,052 | ||||||||||||
| Costs of goods sold and services: | ||||||||||||||||
| Cost of product revenue | 7,236 | 9,921 | 14,269 | 20,667 | ||||||||||||
| Cost of service and other revenue | 4,655 | 4,868 | 9,152 | 9,115 | ||||||||||||
| Total costs of goods sold and services | 11,891 | 14,789 | 23,421 | 29,782 | ||||||||||||
| Gross profit | 19,138 | 8,711 | 36,064 | 23,270 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 5,946 | 6,625 | 10,666 | 13,659 | ||||||||||||
| Selling, general, and administrative | 21,591 | 27,045 | 42,474 | 52,757 | ||||||||||||
| Other lease costs | 1,162 | — | 1,938 | — | ||||||||||||
| Restructuring | — | — | (33 | ) | — | |||||||||||
| Total operating expenses | 28,699 | 33,670 | 55,045 | 66,416 | ||||||||||||
| Loss from operations | (9,561 | ) | (24,959 | ) | (18,981 | ) | (43,146 | ) | ||||||||
| Interest income, net | 3,886 | 552 | 7,335 | 604 | ||||||||||||
| Other expense, net | (154 | ) | (358 | ) | (146 | ) | (575 | ) | ||||||||
| Loss before income taxes | (5,829 | ) | (24,765 | ) | (11,792 | ) | (43,117 | ) | ||||||||
| Income tax (expense) benefit | (235 | ) | (137 | ) | (375 | ) | 62 | |||||||||
| Net loss | $ | (6,064 | ) | $ | (24,902 | ) | $ | (12,167 | ) | $ | (43,055 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.16 | ) | $ | (0.67 | ) | $ | (0.33 | ) | $ | (1.17 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 37,494 | 36,922 | 37,411 | 36,887 | ||||||||||||
Quanterix Corporation | ||||||
Consolidated Balance Sheets | ||||||
(Unaudited and in thousands) | ||||||
June 30, 2023 | December 31, 2022 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 329,525 | $ | 338,740 | ||
| Accounts receivable | 24,423 | 19,017 | ||||
| Inventory | 18,156 | 16,786 | ||||
| Prepaid expenses and other current assets | 6,954 | 6,860 | ||||
| Total current assets | 379,058 | 381,403 | ||||
| Restricted cash | 2,686 | 2,597 | ||||
| Property and equipment, net | 18,328 | 20,162 | ||||
| Intangible assets, net | 6,476 | 7,516 | ||||
| Operating lease right-of-use assets | 20,380 | 21,223 | ||||
| Other non-current assets | 2,282 | 1,298 | ||||
| Total assets | $ | 429,210 | $ | 434,199 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 3,238 | $ | 3,836 | ||
| Accrued compensation and benefits | 7,525 | 10,658 | ||||
| Accrued expenses and other current liabilities | 6,777 | 5,133 | ||||
| Deferred revenue | 10,421 | 8,644 | ||||
| Operating lease liabilities | 3,986 | 2,687 | ||||
| Total current liabilities | 31,947 | 30,958 | ||||
| Deferred revenue, net of current portion | 1,304 | 1,415 | ||||
| Lease liabilities, net of current portion | 39,378 | 41,417 | ||||
| Other non-current liabilities | 1,225 | 1,469 | ||||
| Total liabilities | 73,854 | 75,259 | ||||
| Total stockholders’ equity | 355,356 | 358,940 | ||||
| Total liabilities and stockholders’ equity | $ | 429,210 | $ | 434,199 | ||
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a U.S. GAAP basis, we present non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations, which are calculated by including shipping and handling costs for product sales within cost of goods sold instead of within selling, general, and administrative expenses. Management uses these non-GAAP measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. Management believes that presentation of these non-GAAP measures provides useful information to investors in assessing our operating performance within our industry and in order to allow comparability to the presentation of other companies in our industry where shipping and handling costs are included in cost of goods sold for products. Management also uses these non-GAAP measures as a factor in assessing our progress a
